IISER Unveils Rapid Nanotech Test for Turner Syndrome
Researchers at IISER Berhampur have developed an innovative biosensor for rapid Turner syndrome detection. This rare genetic condition affects roughly one in every 2,000 live female births globally. Specifically, it stems from the complete or partial loss of the second sex chromosome. Patients frequently present with short stature, delayed puberty, primary ovarian insufficiency, and congenital cardiac or renal anomalies.
Conventional diagnosis relies primarily on chromosomal karyotyping. However, karyotype testing requires specialized cytogenetic facilities and certified personnel. Furthermore, clinicians often wait a month or longer to receive definitive laboratory results. Consequently, these logistical delays postpone critical hormonal interventions and clinical management.
Advancing Turner Syndrome Detection with Nanotechnology
To solve these clinical delays, Dr. Parikshit Moitra and his group engineered a dual-component nanomaterial platform. Specifically, the sensing system combines a nucleotide-guided covalent organic framework with gold nanostars. The emissive framework pairs with specialized oligonucleotide probes designed to identify disease-associated chromosomal regions. When target DNA sequences bind, a hierarchical self-assembly occurs between the framework and nanostars. Consequently, this molecular interaction produces a clear, quantifiable optical signal within hours.
Clinical Validation and Diagnostic Implications
Moreover, the research team validated the sensor using clinical patient samples from West Bengal. Collaborators Dr. Sunetra Mondal and Dr. Satinath Mukhopadhyay helped confirm the assay's high sensitivity and molecular selectivity. As a result, the technology demonstrated strong concordance with standard cytogenetic tests. In addition, the assay circumvents cumbersome cell culturing and enzymatic steps. Therefore, it holds tremendous potential as a point-of-care diagnostic tool across resource-constrained healthcare centers.
Future Perspectives for Rare Disease Screening
Beyond Turner syndrome, researchers believe this modular platform can identify other genetic abnormalities. Indeed, switching the capture oligonucleotides could enable screening for numerous chromosomal microdeletions or aneuploidies. However, Dr. Moitra emphasized that widespread adoption requires extensive multicenter clinical trials. Director Ashok Kumar Ganguli also commended the team, noting that rapid diagnostics directly strengthen personalized therapeutic planning. Ultimately, timely diagnosis empowers pediatricians to initiate growth hormone therapy without harmful diagnostic delays.
Frequently Asked Questions
Q1: Why is traditional karyotyping for Turner syndrome considered slow?
Traditional karyotyping requires culturing live lymphocytes, arresting cells in metaphase, and meticulous microscopic inspection by cytogeneticists. Consequently, this laborious laboratory workflow typically takes between three to four weeks before clinicians receive a report.
Q2: How does the IISER Berhampur nanotech platform detect Turner syndrome?
The system couples fluorescent covalent organic frameworks with gold nanostars and oligonucleotide probes. Therefore, when disease-specific DNA signatures bind, the nanomaterials undergo hierarchical self-assembly and emit a measurable optical readout rapidly.
Q3: What are the clinical benefits of rapid Turner syndrome detection?
Early identification allows pediatricians and endocrinologists to start recombinant growth hormone therapy promptly. Furthermore, timely diagnosis ensures early screening for coarctation of the aorta, renal anomalies, and autoimmune thyroid disease.
References
- IISER develops rapid nanotech test for Turner syndrome detection - ETHealthworld
- Neethu KM, Mohanty P, Neelam, et al. Nucleotide Driven Hierarchical Self‐Assembly of Covalent Organic Framework and Gold Nanostar for Molecular Diagnosis of Turner Syndrome. Advanced Functional Materials. 2026;36(70):e77429.
- Indian Institute of Science Education and Research Berhampur. Achieving Genetic Breakthrough: Nanotechnology-Based Biosensing Platform for Rapid Detection of Turner Syndrome. Press Release, August 2026.
